Denali Therapeutics (NASDAQ:DNLI) Releases Earnings Results

Denali Therapeutics (NASDAQ:DNLI) announced its quarterly earnings data on Thursday. The company reported ($0.68) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.17), FiscalAI reports. The business had revenue of $3.60 million during the quarter, compared to the consensus estimate of $2.15 million. During the same period in the prior year, the company earned ($0.72) EPS.

Here are the key takeaways from Denali Therapeutics’ conference call:

• AVLAYAH generated $3.6 million in net product revenue during its first full commercial quarter, with commercial payer coverage exceeding 50% of covered lives. Denali expects Q3 revenue of $10 million–$12 million as access expands and more patients transition to treatment.
• Early launch indicators were stronger than anticipated, including high physician and family engagement and demand extending beyond the initially expected group of highly engaged families. Denali estimates roughly 375 U.S. pediatric patients are currently eligible, with additional opportunity from newly diagnosed children.
• Denali strengthened its balance sheet with $195 million from the sale of its Priority Review Voucher, bringing pro forma cash, cash equivalents, and marketable securities to more than $1.1 billion. Management said the capital supports AVLAYAH commercialization, pipeline development, manufacturing investments, and potential strategic flexibility.
• Two blood-brain-barrier Transport Vehicle programs for Alzheimer’s disease advanced into clinical development: DNL628, a tau antisense oligonucleotide, and DNL921, an anti-amyloid antibody. Initial biomarker and safety or proof-of-concept data are expected in 2027.
• Denali pushed DNL593 data to the first half of 2027, from an earlier expectation of year-end 2026, to obtain longer-term follow-up—particularly for neurofilament light-chain and other biomarkers—and assess a potential accelerated-approval strategy.

Denali Therapeutics Price Performance

Shares of DNLI stock traded up $0.10 during trading hours on Friday, hitting $24.83. The company had a trading volume of 1,749,187 shares, compared to its average volume of 1,757,824. Denali Therapeutics has a 12 month low of $12.58 and a 12 month high of $27.30. The firm has a market capitalization of $3.94 billion, a price-to-earnings ratio of -8.74 and a beta of 1.01. The firm’s fifty day moving average is $23.54 and its 200 day moving average is $21.28. The company has a debt-to-equity ratio of 0.01, a quick ratio of 9.28 and a current ratio of 9.28.

Wall Street Analysts Forecast Growth

DNLI has been the subject of a number of recent research reports. Robert W. Baird set a $34.00 target price on Denali Therapeutics in a research note on Friday. UBS Group raised their target price on Denali Therapeutics from $25.00 to $34.00 and gave the stock a “buy” rating in a research report on Friday. JPMorgan Chase & Co. initiated coverage on shares of Denali Therapeutics in a research note on Monday, July 13th. They set an “overweight” rating and a $29.00 price target on the stock. Wedbush reissued an “outperform” rating and issued a $26.00 price target on shares of Denali Therapeutics in a report on Monday, July 13th. Finally, Morgan Stanley increased their price objective on shares of Denali Therapeutics from $35.00 to $36.00 and gave the company an “overweight” rating in a research note on Thursday, July 23rd. Thirteen research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Denali Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $35.92.

Institutional Trading of Denali Therapeutics

Several institutional investors have recently bought and sold shares of the stock. Quarry LP lifted its holdings in shares of Denali Therapeutics by 60.0% during the fourth quarter. Quarry LP now owns 7,000 shares of the company’s stock valued at $116,000 after acquiring an additional 2,625 shares during the period. WINTON GROUP Ltd bought a new stake in shares of Denali Therapeutics in the 4th quarter worth about $210,000. CIBC Bancorp USA Inc. bought a new stake in shares of Denali Therapeutics in the 3rd quarter worth about $205,000. Russell Investments Group Ltd. increased its position in shares of Denali Therapeutics by 439.4% during the 3rd quarter. Russell Investments Group Ltd. now owns 13,799 shares of the company’s stock worth $200,000 after purchasing an additional 11,241 shares in the last quarter. Finally, Caxton Associates LLP acquired a new stake in shares of Denali Therapeutics during the 2nd quarter worth about $199,000. Institutional investors and hedge funds own 92.92% of the company’s stock.

Denali Therapeutics Company Profile

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.